X4 Pharmaceuticals (NASDAQ:XFOR) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $1.50 price target on the stock. HC Wainwright also issued estimates for X4 Pharmaceuticals’ FY2028 earnings at $0.02 EPS and FY2029 earnings at $0.16 EPS.

Separately, Stifel Nicolaus lowered their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ XFOR opened at $0.53 on Friday. The stock has a fifty day moving average price of $0.59 and a 200 day moving average price of $0.60. X4 Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $1.60. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The company has a market cap of $90.39 million, a PE ratio of -5.89 and a beta of 0.12.

Insider Activity at X4 Pharmaceuticals

In other news, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. Insiders have sold a total of 202,663 shares of company stock worth $91,198 over the last three months. 1.62% of the stock is currently owned by corporate insiders.

Institutional Trading of X4 Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Verition Fund Management LLC purchased a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth approximately $30,000. SG Americas Securities LLC purchased a new position in X4 Pharmaceuticals during the third quarter worth $37,000. Atria Wealth Solutions Inc. acquired a new position in shares of X4 Pharmaceuticals in the fourth quarter worth $44,000. XTX Topco Ltd raised its holdings in shares of X4 Pharmaceuticals by 41.7% in the third quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock worth $106,000 after acquiring an additional 46,397 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in shares of X4 Pharmaceuticals by 103.4% in the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock valued at $166,000 after acquiring an additional 126,296 shares in the last quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.